Resource Hub

Within three weeks of their launch in the United States on Jan. 5, 2026, the newly approved GLP-1 pills for weight loss had been prescribed to about 170,000 people, outpacing the rate of adoption of other GLP-1 medications.  

Previously, GLP-1 medications — which mimic the naturally occurring hormone glucagon-like peptide-1, which regulates

Popular GLP-1 receptor agonist drugs (GLP-1 RAs) for weight loss appear to be similarly effective among patients of different ages, races, and starting weight, with women benefiting somewhat more than men, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

The study examined 64 clinical trials involving semaglutide (Ozempic), dulaglutide (Trulicity), and other drugs in this class. The trials collectively included tens of thousands of patients. The analysis found that on average women who took GLP-1 RAs lost about 11% of their starting weight, compared to about 7% among men. By contrast, the analysis showed similar effectiveness of the agents based on individuals’ age (under 65 versus 65 and older), race, ethnicity, starting body

The Food and Drug Administration (FDA) has approved Wegovy® (semaglutide) tablets, the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of obesity.

Specifically, the Wegovy tablet formulation is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight; and to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the presence of at least 1 weight-related comorbid condition.

The approval was based on data from the randomized, double-blind,